Alternative Recommendation Table

Intervention Mild Moderate Severe Critical Recommendation
Sarilumab Don't Use Don't Use Don't Use Don't Use Sarilumab, an IL 6 inhibitor, has been evaluated as an alternative to Tocilizumab in the treatment of COVID-19 illness. The group recommended that Sarilumab should not be used for Covid-19 illness (moderate certainty evidence, strong recommendation). There was no evidence of benefit compared with placebo in three well conducted randomized controlled trials.
Itolizumab Don't Use Don't Use Don't Use Don't Use The group makes a strong recommendation against the use of Itolizumab among patients with COVID19 infection. In the only trial conducted in 30 people there is no evidence of benefit but some indication of harm
Prone PositioningNo Recommendation Conditional RecommendationConditional RecommendationStrong Recommendation For patients with COVID-19 who are intubated we recommend prone positioning (strong recommendation). For patients who are not intubated and are in hospital with respiratory distress, we recommend prone/semi-prone/lateral positioning (conditional recommendation).
ConvalescentStrong Don't Use Strong Don't Use Strong Don't Use Strong Don't Use Use The group makes a strong recommendation against the use of convalescent for patients with COVID-19 infection. The recommendation was made across all levels of Covid-19 illness. The group is aware that trials are currently investigating its use after early exposure to infection in
AzithromycinStrong Don't Use Strong Don't Use Strong Don't Use Strong Don't Use The group recommends against the use of Azithromycin for COVID-19 infection in all categories of severity (strong recommendation). There was high certainty evidence to demonstrate that Azithromycin did not impact mortality or progression of illness in the treatment of COVID-19 infection.